137 related articles for article (PubMed ID: 34554318)
1. PEAK1 promotes invasion and metastasis and confers drug resistance in breast cancer.
Wang X; Zheng Y; Wang Y
Clin Exp Med; 2022 Aug; 22(3):393-402. PubMed ID: 34554318
[TBL] [Abstract][Full Text] [Related]
2. Pseudopodium enriched atypical kinase 1(PEAK1) promotes invasion and of melanoma cells by activating JAK/STAT3 signals.
Pan M; Yin X; Huang YC
Bioengineered; 2021 Dec; 12(1):5045-5055. PubMed ID: 34365903
[TBL] [Abstract][Full Text] [Related]
3. The PEAK1-PPP1R12B axis inhibits tumor growth and metastasis by regulating Grb2/PI3K/Akt signalling in colorectal cancer.
Ding C; Tang W; Wu H; Fan X; Luo J; Feng J; Wen K; Wu G
Cancer Lett; 2019 Feb; 442():383-395. PubMed ID: 30472186
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling.
Ding C; Tang W; Fan X; Wang X; Wu H; Xu H; Xu W; Gao W; Wu G
Cell Death Dis; 2018 Jul; 9(8):802. PubMed ID: 30038287
[TBL] [Abstract][Full Text] [Related]
5. PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer.
Agajanian M; Campeau A; Hoover M; Hou A; Brambilla D; Kim SL; Klemke RL; Kelber JA
PLoS One; 2015; 10(8):e0135748. PubMed ID: 26267863
[TBL] [Abstract][Full Text] [Related]
6. Circ-PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR-542-3p/CDC5L/PEAK1 pathway.
Zhang C; Li Y; Zhao W; Liu G; Yang Q
Cancer Med; 2020 May; 9(10):3500-3521. PubMed ID: 32167655
[TBL] [Abstract][Full Text] [Related]
7. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Hu D; Li M; Su J; Miao K; Qiu X
Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
[TBL] [Abstract][Full Text] [Related]
8. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.
Huang L; Wen C; Yang X; Lou Q; Wang X; Che J; Chen J; Yang Z; Wu X; Huang M; Lan P; Wang L; Iwamoto A; Wang J; Liu H
Cell Death Dis; 2018 Feb; 9(3):271. PubMed ID: 29449544
[TBL] [Abstract][Full Text] [Related]
9. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].
Wang Y; Kelber JA; Tran Cao HS; Cantin GT; Lin R; Wang W; Kaushal S; Bristow JM; Edgington TS; Hoffman RM; Bouvet M; Yates JR; Klemke RL
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10920-5. PubMed ID: 20534451
[TBL] [Abstract][Full Text] [Related]
10. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
[TBL] [Abstract][Full Text] [Related]
11. A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.
Hamalian S; Güth R; Runa F; Sanchez F; Vickers E; Agajanian M; Molnar J; Nguyen T; Gamez J; Humphries JD; Nayak A; Humphries MJ; Tchou J; Zervantonakis IK; Kelber JA
Oncogene; 2021 Aug; 40(33):5224-5235. PubMed ID: 34239043
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a cytoskeleton-associated kinase PEAK1 and E-cadherin in gastric cancer.
Guo Q; Qin W; Li B; Yang H; Guan J; Liu Z; Li S
Pathol Res Pract; 2014 Dec; 210(12):793-8. PubMed ID: 25445115
[TBL] [Abstract][Full Text] [Related]
13. Dynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical kinase 1 (PEAK1) is essential for the regulation of cell migration and focal adhesion turnover.
Bristow JM; Reno TA; Jo M; Gonias SL; Klemke RL
J Biol Chem; 2013 Jan; 288(1):123-31. PubMed ID: 23105102
[TBL] [Abstract][Full Text] [Related]
14. Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAF
Wang Q; Hao F; Ning L; Sun C
Histol Histopathol; 2024 Jan; ():18705. PubMed ID: 38284248
[TBL] [Abstract][Full Text] [Related]
15. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
Wang Y; Zhao H; Zhao P; Wang X
Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
[TBL] [Abstract][Full Text] [Related]
16. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
17. Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer.
Agajanian M; Runa F; Kelber JA
Biochem Biophys Res Commun; 2015 Sep; 465(3):606-12. PubMed ID: 26297948
[TBL] [Abstract][Full Text] [Related]
18. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.
Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S
Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148
[TBL] [Abstract][Full Text] [Related]
20. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.
Kelber JA; Reno T; Kaushal S; Metildi C; Wright T; Stoletov K; Weems JM; Park FD; Mose E; Wang Y; Hoffman RM; Lowy AM; Bouvet M; Klemke RL
Cancer Res; 2012 May; 72(10):2554-64. PubMed ID: 22589274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
